In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Abivax SA Sponsored ADR, with a price target of $116.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sam Slutsky’s rating is based on several factors that highlight the potential of Abivax SA’s obefazimod. Despite AbbVie’s uncertainty about the mechanism of obefazimod, there is an acknowledgment of its efficacy in induction, which is a promising sign for its future performance. Slutsky likely sees potential in the drug’s ability to differentiate itself in the market once more data, particularly on long-term maintenance and safety, becomes available.
Additionally, while there are concerns about safety profiles, such as headaches and pancreatic enzyme elevations, these are not uncommon in the industry and may be manageable. The financial metrics, including a reasonable cash burn rate and a solid cash runway of approximately 2.5 years, provide a stable foundation for the company’s continued development and potential market success. These elements combined contribute to Slutsky’s optimistic Buy rating for Abivax SA Sponsored ADR.